Recalls / Active ingredient / Empagliflozin
Empagliflozin
6 FDA drug recalls involving the active ingredient “Empagliflozin”.
| Date | Class | Product | Firm |
|---|---|---|---|
| 2023-03-09 | Class II | JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597- | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 2022-01-26 | Class II | Jardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets each), Rx only, Distribu | CARDINAL HEALTHCARE |
| 2021-03-15 | Class II | Synjardy XR (empagliflozin and metformin hydrochloride extended-release) Tablets 25 mg/1000 mg 30 tablets Rx o | Cardinal Health Inc. |
| 2021-03-15 | Class II | Glyxambi (empagliflozin and linagliptin) Tablets 25 mg/5 mg 30 tablets Rx only NDC 0597-0164-30 Dist. by: Boeh | Cardinal Health Inc. |
| 2021-03-15 | Class II | Synjardy XR (empagliflozin and metformin) hydrochloride extended-release) Tablets 12.5 mg/1000 mg 60 tablets R | Cardinal Health Inc. |
| 2018-09-04 | Class II | Synjardy (empagliflozin and metformin hydrochloride) Tablets. 5 mg/1000 mg. Rx only. 180-count bottle. Distrib | Boehringer Ingelheim Pharmaceuticals, Inc. |